Assembly Biosciences Financials - Benzinga

Assembly Biosciences Inc

ASMBNASDAQ

Trade with Public

Trade with Public

$29.80

-0.66-2.17%

At close: Sep 11, 5:00 PM EST

$29.80

N/A

After Hours: Sep 11, 4:00 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Assembly Biosciences Financials

Assembly Biosciences (ASMB) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Assembly Biosciences Q2 EPS $(0.20) Beats $(0.65) Estimate, Sales $13.374M Beat $8.599M Estimate

Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.65) by 69.23 percent. This is a 84.96 percent increase over losses of $(1.33) per share

Benzinga Newsdesk

PRO
Assembly Biosciences Q1 EPS $(0.54) Beats $(0.71) Estimate, Sales $8.213M Miss $9.266M Estimate

Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.71) by 23.94 percent. This is a 53.85 percent increase over losses of $(1.17) per share

Benzinga Newsdesk

PRO
Assembly Biosciences Q4 EPS $1.30 Beats $(0.65) Estimate, Sales $42.469M Beat $7.423M Estimate

Assembly Biosciences (NASDAQ:ASMB) reported quarterly earnings of $1.30 per share which beat the analyst consensus estimate of $(0.65) by 300 percent. This is a 182.8 percent increase over losses of $(1.57) per share

Benzinga Newsdesk

PRO
Assembly Biosciences Q3 EPS $(0.72) Beats $(0.78) Estimate, Sales $10.789M Beat $7.459M Estimate

Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.78) by 7.1 percent. This is a 52.32 percent increase over losses of $(1.51) per share

Benzinga Newsdesk

PRO
Assembly Biosciences' Cash, Cash Equivalents And Marketable Securities Were $75M Projected To Fund Operations Into Mid-2026

Benzinga Newsdesk

PRO
Assembly Biosciences Q2 2025 EPS $(1.33) Beats $(1.36) Estimate, Sales $9.626M Beat $6.262M Estimate

Benzinga Newsdesk